Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutics Inc (OP:OTLC)

0.0518 +0.0018 (+3.60%)
Streaming Delayed Price Updated: 3:14 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,758
Open 0.0525
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0500
Today's Range 0.0491 - 0.0525
52wk Range 0.0170 - 0.0700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial Highlighting Innovative Therapeutics Pipeline
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+52.4%
+52.4%
1 Month
+4.6%
+4.6%
3 Month
+9.7%
+9.7%
6 Month
-5.8%
-5.8%
1 Year
+133.3%
+133.3%

More News

Read More
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs
Via Investor Brand Network
Topics Intellectual Property
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress
Via Investor Brand Network
Topics Intellectual Property
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Showcases Pipeline and CEO’s Intellectual Property Legacy
Via Investor Brand Network
Topics Intellectual Property
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Via News Direct
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
Via News Direct
Topics Death
OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th
From Virtual Investor Conferences
Via GlobeNewswire
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
Via News Direct
Oncotelic Therapeutics’ (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
Via News Direct
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
Via Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Via News Direct
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Via Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
Via News Direct
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
Via Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge
Via Benzinga
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Oncotelic Therapeutics Inc publicly traded?
Yes, Oncotelic Therapeutics Inc is publicly traded.
What exchange does Oncotelic Therapeutics Inc trade on?
Oncotelic Therapeutics Inc trades on the OTC Traded
What is the ticker symbol for Oncotelic Therapeutics Inc?
The ticker symbol for Oncotelic Therapeutics Inc is OTLC on the OTC Traded
What is the current price of Oncotelic Therapeutics Inc?
The current price of Oncotelic Therapeutics Inc is 0.0518
When was Oncotelic Therapeutics Inc last traded?
The last trade of Oncotelic Therapeutics Inc was at 09/16/25 03:14 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS